These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 23696633)

  • 21. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
    Dougados M; van der Heijde D; Sieper J; Braun J; Maksymowych WP; Citera G; Miceli-Richard C; Wei JC; Pedersen R; Bonin R; Rahman MU; Logeart I; Wajdula J; Koenig AS; Vlahos B; Alvarez D; Bukowski JF
    Arthritis Rheumatol; 2014 Aug; 66(8):2091-102. PubMed ID: 24891317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints.
    Varkas G; Jans L; Cypers H; Van Praet L; Carron P; Elewaut D; Van den Bosch F
    Arthritis Rheumatol; 2016 Mar; 68(3):672-8. PubMed ID: 26473982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.
    Fattahi MJ; Jamshidi AR; Mahmoudi M; Vojdanian M; Yekaninejad MS; Jafarnezhad-Ansariha F; Ahmadi H; Rehm BHA; Matsuo H; Cuzzocrea S; Hosseini M; Hashemi SN; Aghazadeh Z; Mirshafiey A
    Int Immunopharmacol; 2018 Jan; 54():112-117. PubMed ID: 29127910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
    Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
    Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
    Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
    J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
    Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
    Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.
    Haibel H; Song IH; Rudwaleit M; Listing J; Hildemann S; Sieper J
    Clin Exp Rheumatol; 2008; 26(2):247-52. PubMed ID: 18565245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).
    Nam JL; Villeneuve E; Hensor EM; Conaghan PG; Keen HI; Buch MH; Gough AK; Green MJ; Helliwell PS; Keenan AM; Morgan AW; Quinn M; Reece R; van der Heijde DM; Wakefield RJ; Emery P
    Ann Rheum Dis; 2014 Jan; 73(1):75-85. PubMed ID: 23912798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
    Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.